Xospata (gilteritinib)

News alerts, weekly reports and conference planners

Company:

Astellas

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
WT1 mutation	Acute Myelogenous Leukemia	WT1 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
BRAF mutation	Acute Myelogenous Leukemia	BRAF mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
CBL mutation	Acute Myelogenous Leukemia	CBL mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
GATA2 mutation	Acute Myelogenous Leukemia	GATA2 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
FLT3‐ITD + WT1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD + WT1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3‐ITD + DNMT3A mutation	Acute Myelogenous Leukemia	FLT3‐ITD + DNMT3A mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3‐ITD	Acute Myelogenous Leukemia	FLT3‐ITD	Acute Myelogenous Leukemia	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B	gilteritinib Sensitive: B - Late Trials gilteritinib Sensitive : B
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C2 – Inclusion Criteria venetoclax + gilteritinib Sensitive : C2	venetoclax + gilteritinib Sensitive: C2 – Inclusion Criteria venetoclax + gilteritinib Sensitive : C2
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	gilteritinib Sensitive: C2 – Inclusion Criteria gilteritinib Sensitive : C2	gilteritinib Sensitive: C2 – Inclusion Criteria gilteritinib Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2	FLT3 inhibitor + gilteritinib Sensitive: C2 – Inclusion Criteria FLT3 inhibitor + gilteritinib Sensitive : C2
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	venetoclax + gilteritinib Sensitive: C2 – Inclusion Criteria venetoclax + gilteritinib Sensitive : C2	venetoclax + gilteritinib Sensitive: C2 – Inclusion Criteria venetoclax + gilteritinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3 mutation + PTPN11 mutation	Acute Myelogenous Leukemia	FLT3 mutation + PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
FLT3 mutation + NRAS mutation	Acute Myelogenous Leukemia	FLT3 mutation + NRAS mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
FLT3 mutation + NRAS mutation + PTPN11 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NRAS mutation + PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	FLT3 mutation + NPM1 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
FLT3-ITD mutation + FLT3 D835	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3 D835	Acute Myelogenous Leukemia	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3	gilteritinib Sensitive: C3 – Early Trials gilteritinib Sensitive : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3	venetoclax + gilteritinib Resistant: C3 – Early Trials venetoclax + gilteritinib Resistant : C3

Xospata (gilteritinib)

Associations
(75)

Associations
(75)

Xospata (gilteritinib)

Associations(75)

Associations(75)

Associations
(75)

Associations
(75)